Efficacy and safety of immune checkpoint inhibitors in solid tumor patients combined with chronic coronary syndromes or its risk factor: a nationwide multicenter cohort study

Background Although, immune checkpoint inhibitors (ICIs) have been widely applied in the therapy of malignant tumors, the efficacy and safety of ICIs in patients with tumors and pre-existing CAD, especially chronic coronary syndromes (CCS) or their risk factors (CRF), is not well identified. Methods...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Immunology, Immunotherapy : CII Immunotherapy : CII, 2024-06, Vol.73 (8), p.159, Article 159
Hauptverfasser:	Liu, Chao, Ruan, Yuli, Huang, Rui, Fang, Lin, Wu, Tong, Lv, Ying, Cui, Luying, Liao, Yuanyu, Wang, Bojun, Chen, Zhuo, Su, Dan, Ma, Yue, Han, Shuling, Guan, Xin, Cui, Jie, Yao, Yang, Wang, Yao, Wang, Mengmeng, Liu, Ruiqi, Zhang, Yanqiao
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adverse events Aged Aged, 80 and over Cancer Research Cohort Studies Disease control Female Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use Immunology Male Medicine Medicine & Public Health Middle Aged Neoplasms - complications Neoplasms - drug therapy Neoplasms - immunology Oncology Retrospective Studies Risk Factors Safety Solid tumors Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!